Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 9/20 | 0.44 |
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TFPI | P10646 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170446 | 0.94 | EGFR (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29485672 | 0.94 | FOLH1 (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29485669 | 0.94 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30170535 | 0.90 | OPRM1 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30170441 | 0.90 | GLO1 (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30170524 | 0.90 | GLO1 (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30170575 | 0.88 | OPRM1 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29421985 | 0.88 | KEAP1 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31589113 | 0.87 | FOLH1 (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29670069 | 0.87 | PTPN1 (0.43) | KEAP1HIF1ABMP1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454551-B2 | Peptides as inhibitors of fibrotic matrix accumulation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2025-10-28 | — | — | US | disclosed |
| US-20220267378-A1 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-08-25 | — | — | US | disclosed |
| EP-3996694-A1 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-114364691-A | Peptides as inhibitors of fibrotic matrix accumulation | 马克斯·普朗克科学促进学会 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454551-B2 | Peptides as inhibitors of fibrotic matrix accumulation | GLS, AGXT, FN1 | GRIN2D 2865/4885GRIN3B 1107/4885GRIN1 796/4885 |
| US-20220267378-A1 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | INHA, GLS, AGXT | GRIN2D 3215/4885GRIN3B 1241/4885GRIN1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.